Loading
journalsJournal
ESMO Open
ESMO's fully open-access journal: trials, real-world studies, ESMO position papers and the Living Guidelines updates, all free to read.
Also called: ESMO Opensrc-esmo-open
Overview
Gold open access under Creative Commons licences. Publishes phase 2 trials and secondary analyses, real-world evidence, health-economics and access studies, and ESMO's own consensus and position statements. Increasingly the venue for the ESMO Living Guidelines and the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) updates.
Publisher
Elsevier · European Society for Medical Oncology
Scope
clinical oncology
Website
Access model
open access
Founded
2016
ISSN
2059-7029
observational20260 citations
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02
The IHC 3+ subgroup result is why the tumour-agnostic label is written at 3+ and not 2+, and why a gallbladder cancer with a strong HER2 stain now has two on-label choices (zanidatamab, trastuzumab deruxtecan) after chemotherapy. Lung toxicity again ran higher than in breast cancer.
rct20260 citations
TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer
Chinese patients in the trial saw the same pattern as the global population: a clear progression-free survival gain, no proven survival gain, and a different rather than heavier side-effect burden, with mouth and eye toxicity in nearly half. It supports use of datopotamab deruxtecan in this setting in China but does not resolve the global trial's missing survival benefit.
rct202530 citations
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib
This is the paper Europe PMC returns for registry id NCT04765059 with the most citations, so it is the natural first reading for anyone following the COMPEL trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
observational2022222 citations
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
One pairing page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
guideline2022146 citations
Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up
One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
guideline2021changed practice160 citations
Epithelioid haemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts
The observation-first approach and the sequencing of sirolimus before other systemic options on the EHE page come from this consensus.
review202148 citations
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape
One of the most cited reviews Europe PMC returns for Trastuzumab deruxtecan in Triple-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
André Ilbawi
Technical Lead for Cancer Control, World Health Organization
Cancer control policyGlobal healthSurgical oncology
The WHO's lead on cancer control, steering the cervical cancer elimination and global breast and childhood cancer initiatives.
Anna Sapino
Scientific Director
Anatomic pathologyBreast cancerMolecular pathology
Pathologist and Scientific Director of the Candiolo Cancer Institute (INOC), Piedmont's oncology IRCCS and an OECI-certified Comprehensive Cancer Centre.
Carlos Barrios
Medical oncologist; Director, Oncology Research Center, Hospital São Lucas PUCRS; Latin American Cooperative Oncology Group
Breast cancerClinical trials in Latin AmericaGlobal oncology
Carlos Barrios is the most visible Latin American voice in global breast cancer trials and a founder of the region's cooperative group LACOG.
Laurence Albiges
Head of the Department of Medical Oncology, Gustave Roussy
Renal cell carcinomaImmunotherapyHIF-2 alpha inhibition
French kidney cancer specialist who co-led CheckMate 214 and the belzutifan trials.
Winette T. A. van der Graaf
Professor of Medical Oncology, Netherlands Cancer Institute and Erasmus MC
Soft-tissue sarcomaAdolescent and young adult oncologyTargeted therapy
Led PALETTE, the trial that made pazopanib the first targeted drug for soft-tissue sarcoma.
Yacine Merrouche
Representative of Institut Godinot to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Yacine Merrouche represents Institut Godinot in the Organisation of European Cancer Institutes, which lists the centre among its members in France.
Notes
top- Holds: ESMO open-access journal for trials, real-world data and guidelines. Access: Open access (CC BY / CC BY-NC-ND).
rctESMO Open 20260 citations
TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer
Chinese patients in the trial saw the same pattern as the global population: a clear progression-free survival gain, no proven survival gain, and a different rather than heavier side-effect burden, with mouth and eye toxicity in nearly half. It supports use of datopotamab deruxtecan in this setting in China but does not resolve the global trial's missing survival benefit.
rctESMO Open 202530 citations
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib
This is the paper Europe PMC returns for registry id NCT04765059 with the most citations, so it is the natural first reading for anyone following the COMPEL trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
observationalESMO Open 2022222 citations
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
One pairing page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
guidelineESMO Open 2022146 citations
Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up
One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
guidelineESMO Open 2021changed practice160 citations
Epithelioid haemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts
The observation-first approach and the sequencing of sirolimus before other systemic options on the EHE page come from this consensus.
reviewESMO Open 202148 citations
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape
One of the most cited reviews Europe PMC returns for Trastuzumab deruxtecan in Triple-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
institutions
people
key papers
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinibEpithelioid haemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of expertsPooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studiesSacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscapeSalivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-upTROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer